Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 9, Issue 5, Pages 587-595Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERA.09.25
Keywords
chemotherapy; clinical trial; immunotherapy; melanoma; targeted therapy
Categories
Ask authors/readers for more resources
Metastatic melanoma remains a lethal disease with a long-term remission rate of less than 10%. Despite many years of research, there has not been a new drug approved in this disease in over two decades. Single-agent chemotherapy is palliative in some patients and there is no advantage of combination chemotherapy or chemo-immunotherapy in randomized trials. High-dose bolus IL-2 produces some long-term remissions and is available for highly selected individuals at selected centers in the USA but is impractical for most patients. Research is ongoing in exploring novel immunotherapeutic and targeted approaches. The status of recently completed and ongoing trials is discussed in this review.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available